These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 20643635)

  • 1. Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and development.
    Wilson C; Terry AV
    Clin Schizophr Relat Psychoses; 2010 Jul; 4(2):124-37. PubMed ID: 20643635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavioral animal models of antipsychotic drug actions.
    Peleg-Raibstein D; Feldon J; Meyer U
    Handb Exp Pharmacol; 2012; (212):361-406. PubMed ID: 23129339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral phenotypes for negative symptoms in animal models of schizophrenia.
    Miyamoto Y; Nitta A
    J Pharmacol Sci; 2014; 126(4):310-20. PubMed ID: 25409784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vitro and In Vivo Models for the Investigation of Potential Drugs Against Schizophrenia.
    Koszła O; Targowska-Duda KM; Kędzierska E; Kaczor AA
    Biomolecules; 2020 Jan; 10(1):. PubMed ID: 31963851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology-driven neurodevelopmental animal models of schizophrenia.
    Meyer U; Feldon J
    Prog Neurobiol; 2010 Mar; 90(3):285-326. PubMed ID: 19857543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent developments in the discovery of novel antipsychotic agents modualating dopamine and serotonin receptors.
    Li X; Ma S
    Curr Drug Targets; 2013 Jul; 14(8):899-918. PubMed ID: 23701299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges and solutions in developing new medications for Schizophrenia.
    J Clin Psychiatry; 2010 Oct; 71(10):1391-9. PubMed ID: 21062617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomics and epigenomics in novel schizophrenia drug discovery: translating animal models to clinical research and back.
    Bosia M; Pigoni A; Cavallaro R
    Expert Opin Drug Discov; 2015 Feb; 10(2):125-39. PubMed ID: 25345474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia.
    Meyer U; Spoerri E; Yee BK; Schwarz MJ; Feldon J
    Schizophr Bull; 2010 May; 36(3):607-23. PubMed ID: 18845557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prenatal treatment with methylazoxymethanol acetate as a neurodevelopmental disruption model of schizophrenia in mice.
    Takahashi K; Nakagawasai O; Sakuma W; Nemoto W; Odaira T; Lin JR; Onogi H; Srivastava LK; Tan-No K
    Neuropharmacology; 2019 May; 150():1-14. PubMed ID: 30831160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurodevelopmental Animal Models Reveal the Convergent Role of Neurotransmitter Systems, Inflammation, and Oxidative Stress as Biomarkers of Schizophrenia: Implications for Novel Drug Development.
    Möller M; Swanepoel T; Harvey BH
    ACS Chem Neurosci; 2015 Jul; 6(7):987-1016. PubMed ID: 25794269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.
    Naber D; Lambert M
    CNS Drugs; 2009 Aug; 23(8):649-59. PubMed ID: 19594194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of biomarkers in the discovery of novel anti-schizophrenia drugs.
    Mikkelsen JD; Thomsen MS; Hansen HH; Lichota J
    Drug Discov Today; 2010 Feb; 15(3-4):137-41. PubMed ID: 20036755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychopharmacological treatment of schizophrenia: what do we have, and what could we get?
    Ellenbroek BA
    Neuropharmacology; 2012 Mar; 62(3):1371-80. PubMed ID: 21420988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.
    Pratt J; Winchester C; Dawson N; Morris B
    Nat Rev Drug Discov; 2012 Jun; 11(7):560-79. PubMed ID: 22722532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical epigenetic models for screening epigenetic drugs for schizophrenia.
    Peedicayil J
    J Pharmacol Toxicol Methods; 2016; 77():1-5. PubMed ID: 26370661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clozapine and GABA transmission in schizophrenia disease models: establishing principles to guide treatments.
    O'Connor WT; O'Shea SD
    Pharmacol Ther; 2015 Jun; 150():47-80. PubMed ID: 25585121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postnatal Phencyclidine (PCP) as a Neurodevelopmental Animal Model of Schizophrenia Pathophysiology and Symptomatology: A Review.
    Grayson B; Barnes SA; Markou A; Piercy C; Podda G; Neill JC
    Curr Top Behav Neurosci; 2016; 29():403-428. PubMed ID: 26510740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential serotonergic agents for the treatment of schizophrenia.
    Garay RP; Bourin M; de Paillette E; Samalin L; Hameg A; Llorca PM
    Expert Opin Investig Drugs; 2016; 25(2):159-70. PubMed ID: 26576669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.